These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25468916)

  • 41. Cell and molecular mechanisms of pathogenesis and treatment of cancer.
    Rew DA
    Postgrad Med J; 1998 Feb; 74(868):77-88. PubMed ID: 9616488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer in light of experimental evolution.
    Sprouffske K; Merlo LM; Gerrish PJ; Maley CC; Sniegowski PD
    Curr Biol; 2012 Sep; 22(17):R762-71. PubMed ID: 22975007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.
    Easwaran H; Tsai HC; Baylin SB
    Mol Cell; 2014 Jun; 54(5):716-27. PubMed ID: 24905005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
    Brioli A; Melchor L; Cavo M; Morgan GJ
    Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Somatic clonal evolution: A selection-centric perspective.
    Scott J; Marusyk A
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):139-150. PubMed ID: 28161395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implications of genetic heterogeneity in cancer.
    Schmitt MW; Prindle MJ; Loeb LA
    Ann N Y Acad Sci; 2012 Sep; 1267():110-6. PubMed ID: 22954224
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumour evolution in hepatocellular carcinoma.
    Craig AJ; von Felden J; Garcia-Lezana T; Sarcognato S; Villanueva A
    Nat Rev Gastroenterol Hepatol; 2020 Mar; 17(3):139-152. PubMed ID: 31792430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changing mutational and adaptive landscapes and the genesis of cancer.
    Liggett LA; DeGregori J
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Constraints in cancer evolution.
    Venkatesan S; Birkbak NJ; Swanton C
    Biochem Soc Trans; 2017 Feb; 45(1):1-13. PubMed ID: 28202655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FastClone is a probabilistic tool for deconvoluting tumor heterogeneity in bulk-sequencing samples.
    Xiao Y; Wang X; Zhang H; Ulintz PJ; Li H; Guan Y
    Nat Commun; 2020 Sep; 11(1):4469. PubMed ID: 32901013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
    Wooten DJ; Quaranta V
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
    Schwarz RF; Ng CK; Cooke SL; Newman S; Temple J; Piskorz AM; Gale D; Sayal K; Murtaza M; Baldwin PJ; Rosenfeld N; Earl HM; Sala E; Jimenez-Linan M; Parkinson CA; Markowetz F; Brenton JD
    PLoS Med; 2015 Feb; 12(2):e1001789. PubMed ID: 25710373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-cell RNA sequencing and bioinformatics as tools to decipher cancer heterogenicity and mechanisms of drug resistance.
    Rosati D; Giordano A
    Biochem Pharmacol; 2022 Jan; 195():114811. PubMed ID: 34673017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineering Multidimensional Evolutionary Forces to Combat Cancer.
    McCoach CE; Bivona TG
    Cancer Discov; 2019 May; 9(5):587-604. PubMed ID: 30992280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intratumoral heterogeneity in cancer progression and response to immunotherapy.
    Vitale I; Shema E; Loi S; Galluzzi L
    Nat Med; 2021 Feb; 27(2):212-224. PubMed ID: 33574607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.
    Eirew P; Steif A; Khattra J; Ha G; Yap D; Farahani H; Gelmon K; Chia S; Mar C; Wan A; Laks E; Biele J; Shumansky K; Rosner J; McPherson A; Nielsen C; Roth AJ; Lefebvre C; Bashashati A; de Souza C; Siu C; Aniba R; Brimhall J; Oloumi A; Osako T; Bruna A; Sandoval JL; Algara T; Greenwood W; Leung K; Cheng H; Xue H; Wang Y; Lin D; Mungall AJ; Moore R; Zhao Y; Lorette J; Nguyen L; Huntsman D; Eaves CJ; Hansen C; Marra MA; Caldas C; Shah SP; Aparicio S
    Nature; 2015 Feb; 518(7539):422-6. PubMed ID: 25470049
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumour heterogeneity in the clinic.
    Bedard PL; Hansen AR; Ratain MJ; Siu LL
    Nature; 2013 Sep; 501(7467):355-64. PubMed ID: 24048068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges.
    Horswell S; Matthews N; Swanton C
    Cancer Lett; 2013 Nov; 340(2):220-6. PubMed ID: 23142290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extensive Clonal Branching Shapes the Evolutionary History of High-Risk Pediatric Cancers.
    Andersson N; Bakker B; Karlsson J; Valind A; Holmquist Mengelbier L; Spierings DCJ; Foijer F; Gisselsson D
    Cancer Res; 2020 Apr; 80(7):1512-1523. PubMed ID: 32041836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selection and adaptation during metastatic cancer progression.
    Klein CA
    Nature; 2013 Sep; 501(7467):365-72. PubMed ID: 24048069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.